University of Groningen
A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency
virus drug treatment
Daskapan, Alper
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Daskapan, A. (2018). A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Samenvatting
Dankwoord
Curriculum Vitae
175
11
Publication list1. Daskapan A, Stienstra Y, Akkerman OW, de Lange WC, Kosterink JG, van der Werf TS,
et al. The Never Ending Struggle Against Development of Drug Resistance. Clin Infect Dis 2015 Jul 1;61(1):137-138.
2. Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, et
al. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015 Feb;45(2):569-571.
3. Daskapan A, Dijkema D, de Weerd DA, Bierman WFW, Kosterink JGW, van der Werf TS,
et al. Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. Br J Clin Pharmacol 2017 Oct;83(10):2325-2329.
4. Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, et al.
Risk factors contributing to a low darunavir plasma concentration. Br J Clin Pharmacol 2018 Mar;84(3):456-461.
5. Klis S, Daskapan A, Akkerman OW, Alffenaar JW, Stienstra Y. Raltegravir and rifampicin
in patients with HIV and tuberculosis. Lancet Infect Dis 2014 Nov;14(11):1046-1047. 6. Van’t Boveneind-Vrubleuskaya N, Daskapan A, Kosterink JG, van der Werf TS, van
den Hof S, Alffenaar JC. Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. PLoS One 2016 Nov 10;11(11):e0166030.
7. Daskapan A, van Hateren K, Stienstra Y, Kosterink J, van der Werf T, Touw D et al.
Development and Validation of a Bioanalytical Method for the Simul- taneous Determination of 14 Antiretroviral Drugs using Liquid Chro- matography-Tandem Mass Spectrometry. Journal of Applied Bioanalysis. 2018;4(2):37-50.
A
quest to optimize the clinical
pharmacology of tuberculosis
and
human immunodefi ciency
virus drug treatment
Alper Daskapan
A quest to optimiz e the c linical phar macolog y of tuber culosis and human immunodefi cienc y vir us dr ug tr ea tment Alper Daska panUITNODIGING
Voor het bijwonen van de openbare verdediging van het proefschrift
A QUEST TO OPTIMIZE THE CLINICAL PHARMACOLOGY OF TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS DRUG TREATMENT
op woensdag 21 november 2018 om 12.45 uur
in de Aula van het Academiegebouw van de Rijksuniversiteit Groningen Broerstraat 5 te Groningen De receptie na afl oop van de promotie vindt plaats in De Spiegelzaal van het Academiegebouw
Alper Daskapan
a.daskapan@umcg.nl
PARANIMFEN
Jeff rey Engelhart
j.j.p.engelhart@gmail.com
Mehdi Alizadeh Aghdam
maghdam@hotmail.com
Sander van Rijn
